HK1093314A1 - Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens - Google Patents
Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigensInfo
- Publication number
- HK1093314A1 HK1093314A1 HK06114232.3A HK06114232A HK1093314A1 HK 1093314 A1 HK1093314 A1 HK 1093314A1 HK 06114232 A HK06114232 A HK 06114232A HK 1093314 A1 HK1093314 A1 HK 1093314A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bordetella
- induces
- cell responses
- adenylate cyclase
- responses against
- Prior art date
Links
- 108010083528 Adenylate Cyclase Toxin Proteins 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 241000588807 Bordetella Species 0.000 title 1
- 230000005867 T cell response Effects 0.000 title 1
- 230000001173 tumoral effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y406/00—Phosphorus-oxygen lyases (4.6)
- C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
- C12Y406/01001—Aodenylate cyclase (4.6.1.1)
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16C—SHAFTS; FLEXIBLE SHAFTS; ELEMENTS OR CRANKSHAFT MECHANISMS; ROTARY BODIES OTHER THAN GEARING ELEMENTS; BEARINGS
- F16C25/00—Bearings for exclusively rotary movement adjustable for wear or play
- F16C25/06—Ball or roller bearings
- F16C25/08—Ball or roller bearings self-adjusting
- F16C25/083—Ball or roller bearings self-adjusting with resilient means acting axially on a race ring to preload the bearing
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16C—SHAFTS; FLEXIBLE SHAFTS; ELEMENTS OR CRANKSHAFT MECHANISMS; ROTARY BODIES OTHER THAN GEARING ELEMENTS; BEARINGS
- F16C27/00—Elastic or yielding bearings or bearing supports, for exclusively rotary movement
- F16C27/06—Elastic or yielding bearings or bearing supports, for exclusively rotary movement by means of parts of rubber or like materials
- F16C27/066—Ball or roller bearings
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16C—SHAFTS; FLEXIBLE SHAFTS; ELEMENTS OR CRANKSHAFT MECHANISMS; ROTARY BODIES OTHER THAN GEARING ELEMENTS; BEARINGS
- F16C33/00—Parts of bearings; Special methods for making bearings or parts thereof
- F16C33/72—Sealings
- F16C33/76—Sealings of ball or roller bearings
- F16C33/78—Sealings of ball or roller bearings with a diaphragm, disc, or ring, with or without resilient members
- F16C33/7886—Sealings of ball or roller bearings with a diaphragm, disc, or ring, with or without resilient members mounted outside the gap between the inner and outer races, e.g. sealing rings mounted to an end face or outer surface of a race
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16C—SHAFTS; FLEXIBLE SHAFTS; ELEMENTS OR CRANKSHAFT MECHANISMS; ROTARY BODIES OTHER THAN GEARING ELEMENTS; BEARINGS
- F16C19/00—Bearings with rolling contact, for exclusively rotary movement
- F16C19/02—Bearings with rolling contact, for exclusively rotary movement with bearing balls essentially of the same size in one or more circular rows
- F16C19/04—Bearings with rolling contact, for exclusively rotary movement with bearing balls essentially of the same size in one or more circular rows for radial load mainly
- F16C19/06—Bearings with rolling contact, for exclusively rotary movement with bearing balls essentially of the same size in one or more circular rows for radial load mainly with a single row or balls
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Mechanical Engineering (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52363203P | 2003-11-21 | 2003-11-21 | |
PCT/EP2004/014086 WO2005053738A1 (en) | 2003-11-21 | 2004-11-19 | Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1093314A1 true HK1093314A1 (en) | 2007-03-02 |
Family
ID=34652257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06114232.3A HK1093314A1 (en) | 2003-11-21 | 2006-12-28 | Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens |
Country Status (11)
Country | Link |
---|---|
US (4) | US20050271679A1 (de) |
EP (2) | EP2193804B1 (de) |
JP (1) | JP4976853B2 (de) |
AT (1) | ATE450272T1 (de) |
CA (1) | CA2546452C (de) |
DE (1) | DE602004024440D1 (de) |
ES (1) | ES2337694T3 (de) |
HK (1) | HK1093314A1 (de) |
PL (1) | PL1684801T3 (de) |
PT (1) | PT1684801E (de) |
WO (1) | WO2005053738A1 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1188446B1 (de) | 2000-09-15 | 2009-08-05 | Institut Pasteur | Proteinhaltigen Vektoren zur Einführung von Moleküle in CD11b exprimirende Zellen |
DE602004024440D1 (de) | 2003-11-21 | 2010-01-14 | Pasteur Institut | Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene |
ATE372784T1 (de) * | 2004-03-18 | 2007-09-15 | Pasteur Institut | Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung. |
EP1894941A1 (de) * | 2006-09-01 | 2008-03-05 | Institut Pasteur | Behandlung von Gebärmutterhalskarzinomen mit einer rekombinanten Adenylat-Cyclase die HPV-Antigene trägt |
EP2061505B9 (de) * | 2006-09-01 | 2013-04-03 | Genticel | Zusammensetzung zur auslösung einer spezifischen ctl-antwort mit einer lympho-ablativen verbindung und einem molekül, das antigene sequenzen enthält und auf professionelle antigen-präsentierende zellen abzielt |
WO2008088771A2 (en) * | 2007-01-12 | 2008-07-24 | Cornell Research Foundation, Inc. | Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens |
CN101636157A (zh) * | 2007-01-12 | 2010-01-27 | 康乃尔研究基金会有限公司 | 作为抗菌干预的新型靶的腺苷酰环化酶 |
EP2478915A1 (de) | 2011-01-24 | 2012-07-25 | Genticel | cyaA-getragene Polypeptid(e) und Verwendung zur Induzierung von therapeutischen und prophylaktischen Immunantworten |
US9345755B2 (en) * | 2012-02-20 | 2016-05-24 | University Of Virginia Patent Foundation | Composition and methods for treating melanoma |
EP2690172A1 (de) | 2012-07-23 | 2014-01-29 | Genticel | CYAA-basierte chimäre Proteine mit einem heterologen Polypeptid und deren Verwendungen bei der Induktion von Immunreaktionen |
EP3217993A1 (de) | 2015-07-20 | 2017-09-20 | Virttu Biologics Limited | Behandlung von krebs mittels infusion von onkolytischem herpes-simplex-virus in das blut |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2290950T3 (es) | 1992-04-21 | 2008-02-16 | Institut Pasteur | Mutantes recombinantes para inducir respuestas inmunitarias especificas. |
US5935580A (en) | 1992-04-21 | 1999-08-10 | Institut Pasteur | Recombinant mutants for inducing specific immune responses |
US5821122A (en) * | 1995-06-07 | 1998-10-13 | Inserm (Institute Nat'l De La Sante Et De La Recherche . .) | Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof |
US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
DE60041183D1 (de) * | 1999-05-06 | 2009-02-05 | Univ Wake Forest | Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen |
KR20020047249A (ko) * | 1999-10-19 | 2002-06-21 | 에드워드 에이. 맥더모트, 주니어 | Mage-a12 항원성 펩티드 및 그의 용도 |
AUPQ776100A0 (en) | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
EP1188446B1 (de) * | 2000-09-15 | 2009-08-05 | Institut Pasteur | Proteinhaltigen Vektoren zur Einführung von Moleküle in CD11b exprimirende Zellen |
EP1489092A1 (de) * | 2003-06-18 | 2004-12-22 | Institut Pasteur | Modifizierte Bordetella Adenylatcyclase mit oder ohne CD11b/CD18 Interaktionsdomäne und seine Verwendungen |
DE602004024440D1 (de) | 2003-11-21 | 2010-01-14 | Pasteur Institut | Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene |
-
2004
- 2004-11-19 DE DE602004024440T patent/DE602004024440D1/de active Active
- 2004-11-19 EP EP09177668.2A patent/EP2193804B1/de not_active Not-in-force
- 2004-11-19 PT PT04819666T patent/PT1684801E/pt unknown
- 2004-11-19 JP JP2006540413A patent/JP4976853B2/ja not_active Expired - Fee Related
- 2004-11-19 CA CA2546452A patent/CA2546452C/en not_active Expired - Fee Related
- 2004-11-19 WO PCT/EP2004/014086 patent/WO2005053738A1/en not_active Application Discontinuation
- 2004-11-19 ES ES04819666T patent/ES2337694T3/es active Active
- 2004-11-19 PL PL04819666T patent/PL1684801T3/pl unknown
- 2004-11-19 EP EP04819666A patent/EP1684801B1/de not_active Not-in-force
- 2004-11-19 AT AT04819666T patent/ATE450272T1/de active
- 2004-11-22 US US10/994,204 patent/US20050271679A1/en not_active Abandoned
-
2006
- 2006-12-28 HK HK06114232.3A patent/HK1093314A1/xx not_active IP Right Cessation
-
2008
- 2008-09-12 US US12/232,250 patent/US9410139B2/en not_active Expired - Fee Related
-
2010
- 2010-03-25 US US12/731,196 patent/US20100310594A1/en not_active Abandoned
-
2013
- 2013-10-25 US US14/063,164 patent/US20140227323A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2005053738A1 (en) | 2005-06-16 |
JP2007511233A (ja) | 2007-05-10 |
US20140227323A1 (en) | 2014-08-14 |
EP2193804A2 (de) | 2010-06-09 |
ES2337694T3 (es) | 2010-04-28 |
EP1684801A1 (de) | 2006-08-02 |
EP2193804A3 (de) | 2010-06-30 |
EP2193804B1 (de) | 2015-12-23 |
ATE450272T1 (de) | 2009-12-15 |
US9410139B2 (en) | 2016-08-09 |
PL1684801T3 (pl) | 2010-07-30 |
PT1684801E (pt) | 2010-03-08 |
DE602004024440D1 (de) | 2010-01-14 |
US20090117143A1 (en) | 2009-05-07 |
CA2546452C (en) | 2015-01-20 |
JP4976853B2 (ja) | 2012-07-18 |
US20050271679A1 (en) | 2005-12-08 |
EP1684801B1 (de) | 2009-12-02 |
CA2546452A1 (en) | 2005-06-16 |
US20100310594A1 (en) | 2010-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1093314A1 (en) | Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens | |
CY1117387T1 (el) | ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ | |
NO994983L (no) | Fremgangsmåte for fremstilling av anti-humane antigenreseptorer, samt anvendelse av disse | |
PL347977A1 (en) | Novel methods for therapeutic vaccination | |
WO2008026071A3 (en) | Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying hpv antigens | |
HUP0302532A2 (hu) | Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások | |
TR199801722T2 (xx) | Peptit imm�nojenler. | |
ATE272113T1 (de) | Melanoma-assoziierte antigene, epitope davon und impstoffe gegen melanoma | |
NO20022531L (no) | Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer | |
PT1198250E (pt) | Proteínas de fusão fc para aumentar a imunogenicidade de antigénios de proteínas e péptidos | |
HUP0500345A2 (hu) | Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására | |
ATE372784T1 (de) | Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung. | |
AU2002245756A1 (en) | Identification and modification of immunodominant epitopes in polypeptides | |
DE60322559D1 (de) | Neue, mhc klasse ii assoziierte peptide | |
DE69131829D1 (de) | Gp75 als tumorimpfstoff gegen melanome | |
HUP0302566A2 (hu) | Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására | |
ATE360642T1 (de) | Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4 | |
TNSN08184A1 (en) | Chimeric antigens and vaccines | |
FI854839A (fi) | Vaccin eller diagnostisk produkt erhaollen fraon peptid, samt daeri anvaendbar polypeptid. | |
ES2199047A1 (es) | Metodo de diagnostico inmunologico de la dirofilariosis pulmonar humana | |
ATE419003T1 (de) | Mycobakterielle proteinantigene für krebstherapie und impfung | |
WO2002014352A3 (en) | Therapeutic compounds for ovarian cancer | |
CY1108790T1 (el) | Συνθεσεις για τη θεραπεια και διαγνωση ωοθηκικου καρκινου | |
TH59159B (th) | สารรวมที่ใช้รักษาภูมิคุ้มกันสำหรับการบำบัดรักษาเนื้องอกที่แสดงแกงกลิโอไซด์ที่มากเกินไป |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20181122 |